Details of the presentation are listed below:
Presentation Title: “Beyond topline results for the oral
(non-peptide) GLP-1R agonist TTP273 in type 2 diabetes: How much and
when?”
Session: OP 19 Novel therapies: Future Opportunities
Presentation
Number: Oral Presentation # 112
Date and Time:
Location:
International Fair of
About TTP273
TTP273 is an oral small molecule that works by activating the GLP-1 receptor. Activation of the GLP-1 receptor leads to the enhancement of insulin secretion and suppression of glucagon production and decreased food intake. There are currently several marketed injectable GLP-1 therapies. These agents have demonstrated notable glucose lowering in addition to weight loss; however, their widespread use may be hindered by the route of administration (injection) and by the high incidence of gastrointestinal side effects (nausea and vomiting).
About Type 2 Diabetes
Type 2 diabetes is a result of the body’s inability to use insulin
properly to control sugar in the bloodstream. Type 2 diabetes represents
up to 95% of diabetes patients, imposing a growing burden on healthcare
systems globally. Diabetes remains the 7th leading cause of death in
About
Forward-Looking Statements
This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Annual Report on Form 10-K and our other filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170907005507/en/
Source:
Investors:
vTv Therapeutics Inc.
Michael Gibralter,
646-378-2938
IR@vtvtherapeutics.com
or
Media:
Pure
Communications Inc.
Christie Teller, 817-907-3619
cteller@w2ogroup.com